tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
Holding SMMT?
Track your performance easily

Summit Therapeutics (SMMT) Income Statement

1,027 Followers

Summit Therapeutics Income Statement

Last quarter (Q2 2024), Summit Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Summit Therapeutics's net income was $-60.38M. See Summit Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
--$ 705.00K$ 1.81M$ 860.00K-
Cost of Revenue
------
Gross Profit
--$ 705.00K$ 1.81M$ 860.00K-
Operating Expense
$ -362.36M$ 88.77M$ 64.28M$ 108.96M$ 73.36M-
Operating Income
$ -158.71M$ -609.65M$ -72.09M$ -86.19M$ -53.19M-
Net Non Operating Interest Income Expense
$ 8.92M$ 6.06M$ 2.89M$ -242.00K$ -251.00K-
Other Income Expense
$ -522.43M$ -520.13M$ -12.27M$ 2.42M$ 576.00K-
Pretax Income
$ -682.61M$ -614.93M$ -78.78M$ -88.60M$ -52.91M-
Tax Provision
----$ -213.00K-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -161.69M$ -614.93M$ -78.78M$ -88.60M$ -52.70M-
Basic EPS
$ 0.31$ -0.99$ -0.41$ -0.96$ -0.76-
Diluted EPS
$ 0.31$ -0.99$ -0.41$ -0.96$ -0.76-
Basic Average Shares
$ 2.81B$ 619.65M$ 193.34M$ 92.24M$ 69.52M-
Diluted Average Shares
$ 2.81B$ 619.65M$ 193.34M$ 92.24M$ 69.52M-
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 87.47M$ 88.77M$ 64.28M$ 108.96M$ 73.36M-
Net Income From Continuing And Discontinued Operation
$ -161.69M$ -614.93M$ -78.78M$ -88.60M$ -52.70M-
Normalized Income
$ -76.58M$ -486.32M-$ -90.96M--
Interest Expense
------
EBIT
$ -116.18M$ -598.47M$ -74.38M$ -88.36M$ -52.66M-
EBITDA
$ -115.13M$ -596.42M$ -71.87M$ -85.91M$ -50.65M-
Currency in USD

Summit Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis